派特灵与膦甲酸钠治疗宫颈人乳头瘤病毒感染的疗效比较  

Comparison of paiteling and foscarnet in the treatment of cervical human papilloma virus infection

作　　者：陈君霞[1] 陶萍萍[2] 王运根[1] 单江静[1] 孟晓华[1] 

机构地区：[1]浙江省绍兴市人民医院妇科,312000 [2]上海市浦东新区人民医院妇科,201200

出　　处：《国际流行病学传染病学杂志》2014年第2期98-100,共3页International Journal of Epidemiology and Infectious Disease

基　　金：绍兴市科技计划重点项目（2011A23017）;上海市浦东新区卫生系统学科带头人培养计划（PWRd2013-09）

摘　　要：目的 比较派特灵与膦甲酸钠治疗宫颈高危型人乳头瘤病毒（HPV）感染的疗效。方法选择高危型HPV持续感染且宫颈薄层液基细胞学技术（TCT）正常或组织病理学诊断≤宫颈上皮内瘤变（CIN）I级，完成随访的125例患者分成派特灵组（47例），按照派特灵用药说明宫颈局部上药6个疗程；膦甲酸钠组（40例），3g／d静脉滴注15d；对照组（38例），仅随访观察。所有研究对象治疗结束后第6、12个月进行HPV复查。结果三组患者中HPVl6单一感染33例（26．4％），多亚型复合感染23例（18．4％）。经12个月随访，HPV转阴情况：派特灵组37例（78．7％），膦甲酸钠组23例（57．5％），对照组22例（57．9％）。HPV转阴率显示，派特灵组高于对照组和膦甲酸钠组，差异有统计学意义（X2=4．293、4．548，P〈0．05），膦甲酸钠组与对照组比较差异无统计学意义（X2=0．001，P〉0．05）。治疗过程中，患者无明显不良反应。结论派特灵对高危型HPV感染有一定的逆转作用，且安全无明显副作用，而膦甲酸钠无明显疗效。Objective To compare the therapeutic efficacy of paiteling and foscarnet sodium on persistent infection of high-risk human papillomavirus （HPV）. Methods One hundred and twenty-five cases of high-risk HPV persistent infection with normal thinprep cytologic test （TCT） report or whose pathology diagnosis ≤ CIN I were selected. They were divided into three groups： paiteling group （n=47）, foscarnet sodium group （n=40）, and control group （n =38）. Paiteling was given according to the instructions for 6 courses; foscarnet sodium was given intravenously 3 g/d for 15 days; and control group was under observation without any treatment. All patients were followed up for 12 months and HPV test was performed at 6 months and 12 months, respectively. Results Patients with single HPV16 infection accounted for 26.4% （33 cases） and patients with multiple infections accounted for 18.4% （23 cases）. After a 12-month follow-up, the HPV negative rate was 78.7%（37 cases） in paitefing group, 57.5%（23 cases） in foscarnet sodium group, and 57.9%（ 22 cases） in control group, with a statistically significant difference between paiteling group and other two groups （X2=4.293,4.548, P〈0.05）, but no statistically significant difference between foscarnet sodium group and control group （X2=0.001, P〉0.05）. No adverse event occurred in all three groups. Conclusions Paiteling is effective and safe on treating persistent infection of high-risk HPV, while foscarnet sodium has hardly any efficacy against the disease.

关 键 词：人乳头状瘤病毒 派特灵 膦甲酸钠 转归 

分 类 号：R737.33[医药卫生—肿瘤]